+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Nasal Polyposis Drug"

Nasal Polyposis - Pipeline Insight, 2024 - Product Thumbnail Image

Nasal Polyposis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
FASENRA (Benralizumab) Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

FASENRA (Benralizumab) Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • September 2022
  • 30 Pages
  • Global
From
From
Nasal Polyposis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Nasal Polyposis - Epidemiology Forecast - 2032

  • Report
  • August 2022
  • 80 Pages
  • Global
From
  • 5 Results (Page 1 of 1)
Loading Indicator

Nasal Polyposis is a condition characterized by the growth of non-cancerous polyps in the nasal passages. It is a common cause of nasal obstruction and can lead to difficulty breathing, loss of smell, and recurrent sinus infections. Treatment for Nasal Polyposis typically involves the use of medications, such as corticosteroids, antihistamines, and antibiotics. In some cases, surgery may be necessary to remove the polyps. The Nasal Polyposis Drug market is a subset of the larger Respiratory Drugs market. It includes medications used to treat Nasal Polyposis, as well as other drugs used to treat other respiratory conditions, such as asthma and COPD. The market is highly competitive, with a number of large pharmaceutical companies offering a variety of products. Some of the companies in the Nasal Polyposis Drug market include GlaxoSmithKline, Merck, Pfizer, AstraZeneca, and Novartis. These companies offer a range of products, including corticosteroids, antihistamines, antibiotics, and other medications. Show Less Read more